skip to content
Primary navigation


Drug - Jakafi (ruxolitinib) [Incyte Corp.]

June 2012

Therapeutic area - myelofibrosis

Approval criteria

Patient has documented diagnosis of intermediate or high-risk myelofibrosis.

Initial authorization will be approved for 6 months.

Subsequent authorization requires documentation of spleen size reduction or symptomatic improvement.

Background information

Jakafi is a kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It is recommended, in the label, that Jakafi be discontinued if, after 6 months, there is no spleen reduction or symptom improvement. 


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top